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ABSTRACT 
 
DIABETES REDUCES THE RATE OF SPUTUM CULTURE CONVERSION IN 
PATIENTS WITH NEWLY DIAGNOSED MULTIDRUG RESISTANT 
TUBERCULOSIS 
 
by 
 
ARGITA DYAH SALINDRI 
 
_____________________ 
 
 
Background: Risk factors for acquired multidrug resistant tuberculosis (MDR TB) are 
well described but risk factors of primary MDR TB is understudied. We aimed to 1) 
assess risk factors for primary MDR TB, including diabetes, and 2) determine if diabetes 
reduced the rate of sputum culture conversion in patients with primary MDR TB. 
 
Methods: From 2011-2014 we conducted a prospective cohort study at the National 
Center for TB and Lung Disease in Tbilisi, Georgia. Adult (≥35 years) patients with 
primary TB were eligible. MDR TB was defined as resistance to at least rifampicin and 
isoniazid. Patients with HbA1c ≥6.5% were defined to have diabetes. Polytomous 
regression was used to estimate the association of patient characteristics with drug 
resistance. Cox regression was used to compare the hazard rate of sputum culture 
conversion in patients with and without diabetes. 
 
Results: Among 318 patients, 268 had drug susceptibility test results. Among patients 
with DST results, 19.4% was primary MDR TB and 13.4% had diabetes. In adjusted 
analyses, diabetes (aOR 2.51 95%CI 1.00 – 6.31) and lower socioeconomic status (aOR 
3.51 95%CI 1.56 – 8.20) were associated with primary MDR TB. Among patients with 
primary MDR TB, 44 (84.6%) converted sputum cultures to negative. The hazard rate of 
sputum culture conversion was lower among patients with diabetes (aHR 0.34 95%CI 
0.13 – 0.87) and among smokers (aHR 0.16 95%CI 0.04 – 0.61). 
 
Conclusions: We found diabetes to be associated with an increased risk of primary MDR 
TB; both diabetes and smoking were associated with a decreased rate of sputum culture 
conversion. 
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CHAPTER I 
INTRODUCTION 
1.1 Background 
 Tuberculosis (TB) is an infectious disease caused by Mycobacterium 
tuberculosis (MTB) that most commonly affects the lungs (WHO, 2013). The 
estimated global incidence of TB is 9.0 million in 2013 and it caused 1.5 million 
deaths in the same year (WHO, 2014). Although the global incidence of 
tuberculosis has decreased over the past 10 years, global TB control now faces 
new challenges posed by of the emergence of drug-resistant strains (Gandhi et al., 
2010). 
Drug-resistant tuberculosis happens when MTB is resistant to anti-
tuberculosis drug(s) and it is classified as either primary or acquired (Cohn, 
Bustreo, & Raviglione, 1997). Primary drug-resistant TB is when a drug-resistant 
strain of MTB infects a person who had no prior history of tuberculosis treatment 
for more than one month, while acquired drug resistant TB is defined as the 
presence of MTB resistant strain in a patient who have history of receiving anti-
TB treatment for at least a month (WHO Geneva & IUATLD, 1998). There are 
several categories for drug-resistant tuberculosis: mono-drug resistant 
tuberculosis, poly-drug resistant tuberculosis, multi-drug resistant tuberculosis, 
and extensively-drug resistant tuberculosis (Vashakidze et al., 2009).  
Multi-drug resistant TB (MDR TB), defined as MTB resistant to at least 
Rifampicin and Isoniazid, is a major challenge in the global TB control and the 
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proportion of global TB cases that are MDR TB continues to increases (Nachega 
& Chaisson, 2003). Approximately 450,000 cases of MDR TB were reported in 
2013 (WHO, 2013b) and it increased to 480,000 cases in 2014 (WHO, 2014). 
Among MDR TB cases in 2013, 3.5% were new TB cases and 20.5% were 
previously treated TB (WHO, 2014). The increasing incidence of MDR is 
simultaneous to the growing prevalence of diabetes worldwide. In 2013, there 
were 382 million adults that had prevalent diabetes mellitus (Shaw, Sicree, & 
Zimmet, 2010).  
An association between diabetes and tuberculosis has been hypothesized 
for centuries but has re-emerged with the rising global prevalence of diabetes 
(Dooley & Chaisson, 2009). Approximately 15-25% of active TB cases are 
attributable to diabetes (Lönnroth, Roglic, & Harries, 2014), but whether diabetes 
is a risk factor for MDR TB remains unclear. While the majority of MDR TB 
cases are due to primary infection (Gandhi et al., 2010), risk factors for MDR TB 
are only well described for acquired MDR TB. A deeper understanding of risk 
factors of primary MDR TB will help TB control programs to break the chain of 
transmission.  
Previous studies reported that diabetes is associated with poor TB 
treatment outcomes (Dooley, Tang, Golub, Dorman, & Cronin, 2009), but 
whether diabetes affects MDR TB treatment is still underreported. Well 
established factors that are associated with poor MDR TB treatment include male 
sex (Johnston, Shahidi, Sadatsafavi, & Fitzgerald, 2009), alcohol use (Shin et al., 
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2006), HIV infection, resistance to fluoroquinolone drugs, and previous history of 
tuberculosis (Kliiman & Altraja, 2009). A previous study reported that diabetes 
was associated with larger median time to initial sputum culture conversion 
(Holtz et al., 2006), but additional studies that investigated if diabetes is 
associated with delayed or longer time to sputum culture are needed. 
Understanding the role of diabetes in MDR TB treatment will help clinicians to 
design better clinical guidelines to improve the quality of patient management.  
Our study was conducted in Country of Georgia, a former Soviet Republic 
with high prevalence and incidence of tuberculosis (Mdivani et al., 2008).  It is 
also one of the European countries with the highest burden of MDR TB, with an 
overall prevalence of MDR TB of 15% in 2009 (Lomtadze et al., 2009). In 2014, 
the prevalence of MDR TB cases was estimated around 11% among new TB 
cases, and 38% among previously-treated TB cases (WHO, 2014).  
1.2 Gap and Purpose of Study 
Previous studies about MDR-TB focused on risk factors of acquired 
MDR-TB. Given that nearly 21% MDR-TB cases worldwide occur among those 
who had never been exposed to anti-TB treatment (WHO, 2014), it is important to 
describe risk factors for primary MDR-TB. This study focuses on newly 
diagnosed or primary MDR TB as the outcome of interest. Using a prospective 
cohort study, we hypothesized that diabetes is associated with primary MDR TB 
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and that diabetes would be associated with poor MDR-TB treatment outcomes. 
Therefore, the objective of this study is to:  
1. Investigate factors associated with the occurrence of newly diagnosed MDR 
TB 
2. Determine the association of diabetes with drug-resistant profile in newly 
diagnosed MDR TB 
3. Investigate the association of diabetes with time to sputum culture conversion 
in newly diagnosed MDR TB patients 
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CHAPTER II 
REVIEW OF LITERATURE 
2.1 Multi-Drug Resistant Tuberculosis 
Resistance to isoniazid and rifampin is caused by mutations in bacterial 
genes (Ormerod, 2005). Resistance to isoniazid is due to mutation in either katG 
or inhA gene (Piatek et al., 2000). KatG gene encodes for catalase-peroxidase, an 
enzyme that is associated with virulence factor for MTB as it can act as the 
protective agent against oxidative stress during the host infection process, 
mutation in this gene will retain katG gene activity (Gagneux et al., 2006). InhA 
gene encodes for InhA as part of FAS-II (fatty acid elongation system) which is 
required to synthesize mycolic acid, mutation in this gene will result in up-
regulation of InhA (Gagneux et al., 2006). Resistance to rifampicin is associated 
with mutation in the rpoB gene, which involves RNA polymerase alterations and 
will lead to the substitution of some highly conserved aminoacids in the resistant 
strain (Telenti et al., 1993). 
Treatment of MDR TB requires prolonged antibiotic use (approximately 
18 months) uses second-line drugs which are less effective (Ormerod, 2005), yet 
more expensive (Liang et al., 2012). MDR TB treatment is also associated with 
serious adverse effects such as ototoxicity, vision impairment, depression, 
hepatitis, and renal failure (Marks et al., 2014). With MDR TB, patients typically 
remain infectious for longer periods of time, both in community and hospital 
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settings. Consequently, it is important to generate new information regarding risk 
factors for primary MDR TB in order to improve clinical guidelines for MDR TB 
patients’ management and to prevent transmission both in community level and 
nosocomial settings.  
2.2  Risk factors for newly diagnosed MDR TB 
Studies to date mainly report risk factors for acquired MDR TB, the 
primary risk factor for acquired MDR TB is non-adherence and poor outcome of 
the previous TB treatment. Previous TB treatment was reported to have increased 
risk of MDR TB in several study sites like Belarus (Skrahina et al., 2013), 
Australia (Francis, Blyth, Colby, Fagan, & Waring, 2014), Uzbekistan (Ulmasova 
et al., 2013), and Baja, California (Bojorquez et al., 2013). Longer duration of 
previous TB treatment (more than 6 months), being treated more than three times 
using anti TB drugs, and the presence of adverse effect during TB treatment are 
also known to be associated with acquired MDR TB (Chen et al., 2013). 
Demographic characteristics that were associated with acquired MDR TB 
include female gender (Atre, D’Souza, Vira, Chatterjee, & Mistry, 2011), being 
under 45 years old (Ulmasova et al., 2013), unemployment (Skrahina et al., 2013),  
history of imprisonment (Skrahina et al., 2013; Ulmasova et al., 2013), history of 
hospitalization in the last 10 years (Ulmasova et al., 2013). Alcohol abusers, 
smokers, and HIV co-infection were reported to increase the risk of MDR TB 
(Skrahina et al., 2013). Patients with history of drug abuse are also at increased 
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risk in developing MDR TB (Anderson et al., 2014). Travel history (ever stayed 
more than 3 months in high prevalence countries) was associated with the 
occurrence of MDR TB in western Australia (Francis, Blyth, Colby, Fagan, & 
Waring, 2014). The presence of cavity on chest radiography and the infection of 
Beijing strain are found to statistically significant with the occurrence of acquired 
MDR-TB (He et al., 2011).  
Only a few studies to date have reported risk factors for primary MDR TB. 
The current established risk factor for primary MDR TB is close contact with 
MDR TB patients. There were only limited and outdated studies that investigated 
the close proximity with MDR TB patients and its relation with the occurrence of 
MDR TB. MDR TB outbreaks also occur at healthcare facilities as the result of 
nosocomial infection (Breathnach et al., 1998). In a study conducted in Rio de 
Janeiro, Brazil, tuberculosis occurred in 17 (7.8%) of 218 healthy people that had 
close contact with 64 MDR TB cases (index).  Samples were collected from 13 of 
17 new TB cases observed. Of those 13 newly diagnosed TB cases,  six (46%) 
had identical drug resistant profile as their index cases (MDR TB cases), 31% had 
different drug resistant profile with their index cases, and the remaining 23% were 
found to be susceptible TB cases (Kritski et al., 1996). This finding indicates that 
close contact with MDR TB cases has higher chance of developing the same 
resistance pattern.  
A recent prospective cohort study conducted in Peru compared the 
incidence of active TB among household contacts with MDR TB index cases 
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versus drug susceptible TB index cases. Among household contacts contacted 
with MDR TB index cases, 3.3% (35/1055) developed active TB and 86% (24/28) 
patients with DST results available were MDR TB. The prevalence of active TB 
among household contacts contacted with drug susceptible TB index case was 
higher 4.8% (114/2362), but MDR TB was only 2% (2/73) among patients with 
DST results available (Grandjean et al., 2015). 
One study conducted in Peru found that 23.2% of subjects studied reported 
to have at least one high risk factors for primary MDR TB including close contact 
with TB patients, previous prophylaxis (LTBI treatment), and tobacco use. 
Although the risk factors did not have a statistically significant association with 
primary MDR TB, the rate of MDR-TB was reported to be higher among patients 
with at least one of these risk factors (Otero et al., 2011).  
Non-adherence during previous latent tuberculosis infection treatment 
(LTBI treatment) may be a risk factor for primary MDR-TB. However, 
chemoprophylaxis for people with LTBI is not commonly used in low- and 
middle-income settings, and therefore data on the association between LTBI 
treatment history and primary MDR TB is limited. However, one study conducted 
in Western Cape Province of South Africa estimated the efficacy of 
chemoprophylaxis given to children <5 years old who had a close contact with 
adult MDR TB index cases. Among 119 children that were followed up, 14 (12%) 
developed active TB. Of those remaining who had not developed the disease, 61 
(51%) were infected and considered as LTBI cases while 44 (37%) were not 
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infected. Those who didn’t develop the disease were prescribed LTBI treatment 
according to susceptibility test of the index cases. After 30 months follow up, 29 
(24%) developed the disease and 64 (54%) were infected. TB disease was lower 
(5%) among children received appropriate LTBI chemoprophylaxis (based on 
index cases’ susceptibility profile) versus children who did not receive 
chemoprophylaxis (20%). This study concluded that appropriate 
chemoprophylaxis might prevent the TB development among children contacted 
with adult MDR TB patients (Schaaf, Vermeulen, Gie, Beyers, & Donald, 1999). 
2.3 Diabetes and drug-resistant tuberculosis 
As MDR TB prevalence increases, the global prevalence of diabetes is 
also becoming another major challenges for global TB control. Diabetes is an 
established risk factors for tuberculosis (Jeon & Murray, 2008), but the 
association between diabetes and drug resistant tuberculosis remains 
controversial. Diabetes has been linked to lower plasma concentration of 
rifampicin (Ruslami et al., 2010), more severe TB infection manifestation (Chang 
et al., 2011), and it is proved to be one of potential risk factors for the 
development of MDR TB (Hsu et al., 2013).  
Diabetes is associated with immunosuppression condition in which 
cytokines and chemokines are up-regulated due to chronic inflammatory state, 
resulting in higher susceptibility to bacterial infection including Mycobacterium 
tuberculosis because the production of reactive oxidative species (ROS) might be 
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altered (Fisher-Hoch et al., 2008). Although there is not enough evidence to date 
to say that the resistant strain of Mycobacterium tuberculosis is more infectious 
than the susceptible strain  (Anderson et al., 2014), a study in Taiwan showed that 
the rate of drug-resistant tuberculosis (resistant to Isoniazid, Rifampicin, and 
Streptomycin) is higher among immunocompromised group (including patients 
with diabetes, lung cancer, end-stage renal disease, autoimmune disease) when 
being compared to immunocompetent group (25.8% vs 17.0%). There was only 
one MDR TB patient in the immunocompromised group and none in the 
immunocompetent group (Jiang, Yen, & Wang, 2011).  
A case-control study conducted in Bangladesh showed that the adjusted 
odds of developing MDR TB was two times greater among patients with diabetes 
(Rifat et al., 2014). This finding is similar to a study conducted in Texas-Mexico 
border. The adjusted odds of developing MDR TB among patients with diabetes 
in a Texas site was 2.14 (95%CI 1.10-4.17) and 1.80 (95%CI 1.13-2.87) in 
Mexico site. Diabetes was prevalent among MDR-TB patients (31.6%) in overall 
study population. When breaking down the study site, Texas had higher rates of 
diabetes among its MDR TB patients (36.7%) compared to the Mexico site 
(29.5%) (Fisher-Hoch et al., 2008). 
In a case control study conducted in New York City, the rate of MDR TB 
was higher among diabetes group (36%) compared to non-diabetes group (10%) 
with the crude odds ratio of 5.1 (95% CI 2.1-12.5) (Bashar, Alcabes, Rom, & 
Condos, 2001). A very similar finding was reported in a recent publication from 
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Mexico, which reported that the rate of diabetes is significantly different in MDR 
TB (47.2%) versus non MDR TB patients (28.1%) (OR 2.29; 95% CI 1.08 - 4.86) 
(Gómez-Gómez et al., 2015).  
Some contradictive results were reported when comparing the association 
of diabetes and MDR TB among newly diagnosed patients and previously treated 
cases. A study in Taiwan found that diabetes can act as both protective factor for 
newly diagnosed MDR TB (aOR 0.95 95% CI 0.34-2.68) and independent risk 
factors for acquired MDR TB (aOR 1.52 95% CI 0.59-3.95)(Hsu et al., 2013). 
The rate of MDR TB among patients with diabetes was not significantly different 
among patients with and without diabetes in Thailand (Duangrithi et al., 2013), 
Korea (Reed et al., 2013), and Taiwan (Chang et al., 2011). 
2.4 Diabetes and culture conversion among MDR TB patients 
Although the role of diabetes and poor TB outcome has been reported 
worldwide (Baker et al., 2011), the role of diabetes and MDR TB treatment 
outcome is still understudied. Delayed culture conversion, indicators of 
progressive TB pulmonary disease and markers for additional drug resistance 
(Kurbatova et al., 2011), can be one of the predictors for poor MDR TB outcome. 
Evaluating the culture conversion time among patients can also be used as 
parameter whether the regimen given to the patient is effective or not (Laserson et 
al., 2005).  
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Some previous studies were conducted to examine the associations 
between diabetes and TB drugs pharmacokinetic. A clinical study with Indonesia 
as the study setting reported that there was no significant difference for the 
maximum plasma concentration, time to reach maximum concentration, and the 
half-lives for rifampin, pyrazinamide, and ethambutol during the intensive phase 
of TB treatment between patients with and without diabetes (Ruslami et al., 
2010). However, two studies reported that diabetes is associated with lower 
concentration of rifampicin among TB patients, making it less potent for TB 
treatment (Alisjahbana et al., 2007; Nijland et al., 2006). The pharmacokinetics of 
second line TB drugs among patients with diabetes is still understudied. Further 
study to investigate the association between glycemic condition or the interaction 
between diabetes drug and the second line TB drugs is needed. Such study will 
give an idea if diabetes will reduce the efficacy of second-line TB drugs which 
can result in delayed culture conversion during MDR TB treatment.  
In a multinational study involving 5 countries with DOTS-plus program, 
risk factors associated with delayed culture conversion included older age, 
alcoholism, cavitary disease, positive result in baseline AFB smear, history of 
previous treatment, poor outcome on previous TB treatment, and the presence of 
additional drug resistance (Kurbatova et al., 2012). A study in South Africa 
showed that 32% of MDR TB patients had culture conversion within the first two 
months of their MDR TB treatment. In the same study, cavity score and positive 
AFB smear were found to be associated with longer time to achieve culture 
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conversion (Brust et al., 2013). Similar finding were reported from a study in 
Peru, where the majority of the patients (87.7 %) converted with a median of 59 
days. In the same study, aggressive regimen was found to have association with 
the culture conversion with the hazard ratio (HR) of 1.40 (Tierney et al., 2014). A 
study conducted in India showed that more than half (68%) of MDR TB patients 
studied converted within 9 months of their treatment. Of those who did not 
converted had poor MDR TB treatment outcomes (15 died, 18 default, 8 failed) 
(Jain, Desai, Solanki, & Dikshit, 2014).  
Some interesting findings have been reported in regards of culture 
conversion time and the presence of some co-morbidity factors. Low body mass 
index (BMI) is reported to have association with delayed culture conversion in the 
study conducted in Indonesia (Putri et al., 2014). A study in Botswana reported 
that the median time of culture conversion was smaller in HIV infected patients 
(78 days) compared to non-HIV infected patients (95 days) with the unadjusted 
HR of 0.9 (Hafkin et al., 2013).  
The role of diabetes in delayed culture conversion time has been 
understudied over the past few years. A study conducted in Latvia reported that 
concurrent diabetes was found to be associated with larger median time to culture 
conversion time with the p-value of 0.024 (Holtz et al., 2006).  Our previous study 
in Georgia showed that the proportions of MDR TB patients with diabetes who 
got their culture converted is not significantly different from MDR TB patients 
without diabetes (Magee et al., 2014).  
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2.5 Summary of literature review 
  Highlights from the literature review of previous studies include:  
 Studies to date primarily examined  risk factors for acquired MDR TB 
while risk factors for primary MDR TB remain understudied 
 The association between diabetes and drug resistant tuberculosis is 
controversial, as demonstrated by various discrepant results across study 
locations and populations 
 The association between diabetes and sputum culture conversion is under 
studied 
15 
CHAPTER III 
MANUSCRIPT 
Introduction 
Annually there are an estimated 9 million new cases of active tuberculosis (TB) 
disease including 480,000 cases of multidrug-resistant (MDR) TB, defined as resistance 
to at least rifampicin and isoniazid [1]. Importantly, the incidence of MDR TB is 
increasing rapidly; for example, there were 450,000 cases in 2012 [2] compared to 
290,000 in 2010 [3]. Simultaneous to the increase of MDR TB, the global prevalence of 
type 2 diabetes mellitus (diabetes) has increased substantially in the past ten years and in 
2013 an estimated of 382 million adults had prevalent diabetes[4]. While diabetes is an 
established risk factor for active TB and an estimated 15-25% of active TB cases are 
attributable to diabetes [5], whether diabetes is associated with MDR TB remains unclear.  
Although diabetes is associated with a 2-3 fold increased risk of active TB [6], 
whether it is associated with either primary or acquired MDR TB remains controversial. 
Previous studies reported that diabetes is associated with MDR TB [7], [8] while others 
reported no increased prevalence of MDR TB among patients with diabetes compared to 
those without diabetes [9], [10]. The majority of global MDR TB cases are due to 
primary infection with a resistant strain [11], but risk factors for MDR TB are only well 
established for acquired MDR TB. Established risk factors for acquired MDR TB include 
female gender [12], previous TB treatment [13], [14], HIV infection [15], and infection 
of Beijing strain [16]. While less in known about risk factors for primary MDR TB, 
studies have reported that close contact with MDR TB patients, either household [17] or 
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nosocomial contact [18], was associated with primary MDR TB. Diabetes is associated 
with immunosuppression [19], but there is not enough evidence to date to suggest that 
patients with diabetes are at increased risk of primary MDR TB infection. Improved 
global control of TB will require improved prevention of primary MDR TB including a 
better understanding of the relationship between diabetes and risk of MDR TB. 
Diabetes is also associated with poor TB treatment outcome [20], but whether 
diabetes affects response to MDR TB treatment outcomes is understudied. Risk factors 
for poor MDR TB treatment outcome are well described and include male gender [21], 
alcohol abuse [22], HIV infection, previous TB treatment, resistance to ofloxacin, and 
positive AFB smear at the start of anti TB treatment [23]. Given the paucity of 
information on the relationship between diabetes and MDR TB, the primary objective of 
this study was to determine the association of diabetes with drug-resistant profiles in 
patients without previous TB treatment. We also aimed to investigate the association 
between diabetes and time to sputum culture conversion in newly diagnosed MDR TB 
patients. 
Methods 
Setting and Study Design 
We performed a prospective cohort study conducted between 2011 and 2014 at 
the National Center for TB and Lung Disease (NCTLD), the primary care center for the 
National TB Program in Tbilisi, Georgia. Patients aged 35 and older with new pulmonary 
laboratory confirmed TB (by Mycobacterium tuberculosis culture and/or sputum smear-
positive) or clinically diagnosed (based on clinical symptoms and chest x-ray findings) 
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were eligible. Retreatment cases or patients with prior history of TB were excluded. 
Patients with MDR TB were followed during treatment to evaluate sputum culture 
conversion time.  
Definitions 
 The primary outcomes in this study were presence of primary MDR TB and time 
to sputum culture conversion. We classified drug resistance pattern into three categories: 
fully susceptible, intermediate resistance, and multi or extensively drug resistant 
tuberculosis (M/XDR). Drug susceptibility tests were performed at the Georgia National 
TB Reference Laboratory (NRL) using LJ absolute concentration method, as previously 
described [24]. Fully susceptible TB was defined as TB that was susceptible to all of 
first-line TB drugs used in Georgia (Isoniazid, Rifampin, Ethambuthol, and 
Streptomycin). Intermediate resistance was defined as TB resistant to at least one first-
line TB drug but not MDR TB. Included in intermediate resistance were patients with 
mono-drug resistant TB, poly-drug resistant TB, and patients with missing no more than 
3 first-line drug susceptibility test results. Multi-drug resistant TB was defined as TB that 
was resistant to at least isoniazid and rifampin. We combined MDR and XDR TB cases 
as the prevalence of XDR-TB was very low in this study. We excluded patients with 
missing drug susceptibility results for all TB first line drugs. The second primary 
outcome, time to culture conversion, was defined as time (in days) from the beginning of 
TB treatment until the date of the first of two consecutive negative culture results that 
were at least 30 days apart. We classified MDR TB treatment outcome as favorable and 
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poor outcome, favorable included cured and patients who completed the treatment and 
patients who defaulted, failed, or died were defined to have poor outcome [25].  
Diabetes status was determined by measuring patients’ glycosolated hemoglobin 
(HbA1c) level within 60 days of TB treatment initiation. We classified diabetes status 
based on the 2014 American Diabetes Association clinical guidelines [26], patients with 
HbA1c ≥6.5% and/or with a history of diabetes diagnosis were considered to have 
diabetes.  
Demographic and behavioral risk factor information was collected using a 
questionnaire at the time of enrollment. Participants were interviewed in Kartuli (official 
language of Georgia), or Russian. Patients were asked to self-report their education 
attainment, socioeconomic status, smoking status and alcohol use. Education attainment 
was classified into three categories: less than high school completed, high school degree, 
and more than high school. Socioeconomic status was categorized into three groups 
based on tertiles of income.  We classified smoking status as never, past and current. We 
classified patients who reported no current or past use of tobacco as never smokers. 
Those who reported previous habitual or frequent use of tobacco were considered as past 
smoker. Those who smoked daily or less than daily were considered current smokers. 
Patients were also asked about their alcohol use with the classification of never; 
intermediate (≤ 4 drinks per setting), and heavy (≥ 5 drinks per setting).  
Statistical Analyses  
All statistical analyses were performed using SAS version 9.4. A two sided p-
value <0.05 was considered significant in all analyses. Bivariate analyses for categorical 
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data were performed using polytomous logistic regression to examine association 
between patient characteristics and drug resistance profile. Continuous data were 
analyzed using Kruskal-Wallis test. Multivariable logistic regression models were used to 
estimate the association of diabetes with drug resistance profile. Hazard assessment was 
performed using Cox proportional hazard models to evaluate culture conversion time 
among MDR TB patients. Patients were censored if in the end of MDR TB treatment they 
did not have documentation of sputum conversion, were lost to follow up, or died (with 
no documentation of prior conversion). Proportional hazard assumptions were assessed 
graphically, with goodness-of-fit tests, and using time-dependent models [27]. Covariates 
included in multivariable models were based on previous literature and observed 
bivariate associations with the primary exposure and outcomes.  
Ethical approval 
 This study has been reviewed and approved by Institutional Review Board at the 
NCLTD and Emory University.  
Results 
Study Samples and Baseline Characteristic 
During the study period 586 eligible TB patients were treated at NCLTD in Tbilisi; 324 
were screened for the HbA1c and 318 were enrolled in this study. Of the 318 patients, 
268 (84.3%) had drug susceptibility test results and were included in final analyses. 
Among 268 patients with TB, 52 (19.4%) were M/XDR TB patients. The median HbA1c 
was 5.4 (IQR 5.1 – 5.7) and the prevalence of diabetes was 13.4% (36/268). 
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The majority of patients were male (75.4%) and the median age was 49 years (IQR 42 -
58). Most participants finished high school (56.9%) and were in the lower and middle 
socioeconomic status (61.9% combined) with the median income of $118 USD (IQR 41 – 
412). Only 8.2% patients were internally displaced and previous imprisonment was 
reported by 14.6% of participants. Self-reported current smoking was high (49.1%) and 
any alcohol use was reported among 70.0%. 
Diabetes and Drug Resistance Profile  
Of the 268 patients with available drug susceptibility test results, 137 (51.1%) were fully 
susceptible to all first line drugs, 79 patients (29.5%) had intermediate resistance, and 49 
(18.3%) had MDR TB, and 3 (1.1%) had XDR TB (Table 1). The prevalence of MDR TB 
among patients with diabetes was 30.6% versus 17.7% among patients without diabetes 
(p=0.07). In an adjusted model the odds of MDR TB was significantly higher among 
patients with diabetes compared to patients without diabetes (aOR 2.51 95% CI 1.00 – 
6.31) (Table 2). In the same adjusted model, the odds of intermediate resistance was 
significantly higher among past smokers (aOR 3.94 95% CI 1.25 – 12.47) and current 
smokers (aOR 95% CI 4.56 1.149 – 14.02), while the odds of MDR TB was higher 
among patients with lower socioeconomic status (aOR 3.51 95% CI 1.56 – 8.20). 
Diabetes and culture conversion time among MDR TB patients 
Among 52 M/XDR TB patients, 44 (84.6%) converted sputum cultures to negative with a 
median time of 61 days (IQR 31.0-91.5) (Table 3). Median time to culture conversion 
among MDR TB patients with diabetes was 87 days (IQR 35-99) vs 38 (31-84) in MDR 
TB patients without diabetes (p=0.07). In an unadjusted model, the rate of sputum culture 
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conversion was lower among MDR TB patients with diabetes (cHR 0.75 95% CI 0.36 – 
1.53) and current smokers (cHR 0.44 95% CI 0.19 – 0.98). After adjusting for age, sex, 
socioeconomic status, HIV status, cavitary disease, and grade of AFB smear, we found 
that the hazard rate of sputum culture conversion to be significantly lower among MDR 
TB patients with diabetes (aHR 0.34 95% CI 0.13 – 0.87) compared to MDR TB patients 
without diabetes. In the same model, we found that the hazard rate of sputum culture 
conversion was also lower among current smokers (aHR 0.16 95% CI 0.04 – 0.61) 
compared to non-smokers.  In a supplementary secondary model we found that age (aHR 
0.39 95% CI 0.16 – 0.97) was associated with lower hazard rate of sputum culture 
conversion, while and cavitary disease was associated with higher hazard rate of sputum 
culture conversion (aHR 3.39 95% CI 1.25 – 9.23) among patients with MDR TB.  
At the end of follow-up, 50 (96.2%) patients with MDR TB had treatment 
outcome information. One patient had missing treatment outcome and one patient 
remained on treatment. Of 50 patients who had treatment outcome information, 54% 
(27/50) had favorable treatment outcome (cured or completed) while 46% (23/50) others 
had poor treatment outcome (died or defaulted). Of those who had poor treatment 
outcome, 21.74% (5/23) had diabetes. The risk of poor treatment outcome was similar 
among those with diabetes (45.4%) and those without diabetes (46.1%). The risk of poor 
treatment outcome among those who reported current use of tobacco was 72.7% 
compared to 25.0% among those who reported past or no history of tobacco use 
(p=<0.01).    
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Discussion 
 Overall, we found that diabetes was a risk factor for primary MDR TB and that 
among patients with MDR TB the rate of sputum culture conversion was lower in those 
with diabetes. These associations were observed even after adjusting for confounding 
factors. Our findings suggest diabetes may have a more important role in MDR TB and 
response to MDR TB treatment than previously indicated. Importantly, we also observed 
that lower household income was associated with MDR TB and that current smoking was 
associated with intermediate drug resistance. We also reported that patients with MDR 
TB who reported to be current smokers has a significantly lower rate of sputum culture 
conversion.  
 Diabetes is associated with altered immune function likely leading to increased 
susceptibility to bacterial infections like Mycobacterium tuberculosis [7]. Whether 
resistant strains of M. tuberculosis are more infectious than the susceptible strains is 
unknown [28], however, previous studies reported that mutations in bacterial genes may 
increase pathogenicity. For example, a molecular analysis of isoniazid-resistant strains 
found that katG gene mutations in isogenic MTB resulted in increased coding of catalase-
peroxidase, an enzyme that may prevent bacterial susceptibility to oxidative stress during 
the host infection process [29]. Given MDR TB patients in our study were due to primary 
infection, and resistant to isoniazid and rifampin, it is possible that resistant MTB strains 
were better able to survive host oxidative stress among patients with diabetes in whom 
the production of reactive oxidative species (ROS) is likely reduced due to glycation [7].    
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  Whether diabetes is associated with increased prevalence or risk of MDR TB has 
been inconsistently reported in previous studies. Consistent with our findings that patients 
with diabetes have more than twice the odds of MDR TB, a retrospective cohort study 
conducted on the Texas-Mexico border also found that the risk of developing MDR TB 
was higher among patients with diabetes among both Texas (aOR 2.14 95% CI 1.10 – 
4.17) and Mexican patients (aOR 1.80 95% CI 1.13 – 4.17) [7]. A case control study 
conducted in Bangladesh also reported greater risk of MDR TB among patients with 
diabetes (OR 2.25 95% CI 1.4 – 3.6) [30]. However, both Texas and Bangladesh studies 
included patients with previously treated TB. A cross-sectional study conducted in 
Taiwan reported that diabetes did not increase the odds of prevalent MDR TB among 
newly diagnosed patients (aOR 0.95 95% CI 0.34 – 2.68) [9].  
  Few other studies reported that diabetes status is associated with time lower rate 
of sputum culture conversion. Consistent with this study’s findings, our previous work 
reported lower but not significant culture conversion rate among patients with diabetes 
(aHR 0.95, 95% CI 0.71–1.28) in an adjusted model [31]. A multinational cohort of 
patients with MDR TB also reported lower but non-significant unadjusted rate of sputum 
culture conversion among patients with diabetes (cHR 0.76 95% CI 0.54 – 1.06) [32]. 
Also consistent with our finding, a retrospective cohort study conducted in Latvia 
reported that concurrent diabetes is associated with longer time to culture conversion with 
difference in initial conversion time of 373 days (95% CI 23 – 1725; p=0.02) [33].  
Similar to this study’s findings, previous studies consistently report that low SES 
and smoking play critical roles in risk of TB and response to TB treatment. For example, 
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studies that examined risk factors for MDR TB also reported that lower socioeconomic 
status is associated with resistance [34]–[36]. Consistent with our finding that patients 
with lower socioeconomic status had three times greater odds of MDR TB, a study in 
Turkey reported that the risk of MDR TB is increased by 6 fold among patients with low 
socioeconomic status. Higher prevalence of MDR TB among lower socioeconomic 
groups in our study suggests that the infection may be related to poverty. We run a 
separate bivariate analysis and found that the proportion of contacts with MDR TB 
patients is significantly different in lower socioeconomic group (10.1%) versus higher 
socioeconomic group (2.4%) (p=0.02). Increasingly studies have found smoking to be an 
important risk factor for poor TB treatment outcome [37], [38] and increased risk of 
relapse after successful treatment [39]. Although the association between smoking and 
poor MDR TB treatment outcomes is under studied, this study’s finding that smoking 
lowers the rate of sputum culture conversion is consistent with our previous study in 
Georgia (aHR 0.82, 95%CI 0.71 – 0.95) [31]. Our results suggest that low SES is a risk 
factor for MDR TB and that smoking importantly delays culture conversion rates among 
MDR TB patients. In regions with high rates of MDR TB like Georgia, expanded 
surveillance and prevention programs should be targeted among low SES settings where 
smoking rates are typically higher. 
This study was subject to limitations. First, our study population came from one 
TB hospital in Tbilisi and the generalizability to other countries may be limited. 
Nonetheless, patients from the entire country of Georgia seek care at the facility where 
our study was conducted and consequently findings are likely relevant to other former 
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Soviet Republics and other low- and middle-income settings with high rates of MDR TB.  
Moreover, our study was conducted in a TB facility supported with high quality 
laboratory testing so that the lab results including the drug sensitivity test results were 
reliable and bias due to misclassification was of limited concern. Second, 15.7% of 
enrolled patients in our study did not have complete DST available and were excluded 
from analyses. We compared basic demographic and clinical characteristics among 
patients with and without DST results. We found that patients with missing DST were 
older (median 56  vs 49 years) but similar with respect to gender, socioeconomic status, 
baseline AFB, and HIV status. We do not believe missing DST introduced internal 
systematic error in our results. More importantly, only two patients with MDR TB had a 
missing treatment outcome, providing an exceptional follow-up rate in our prospective 
analyses (96.2%). Third, some of the key covariates in our analysis, like smoking status 
and alcohol use, were self-reported and may have resulted in misclassification. However, 
previous studies have reported high validity of self-reported smoking and alcohol use 
behaviors compared to biomarker measurement [40], therefore we do not believe the 
misclassification led to substantial bias in our reported measures of association. 
Conclusion 
Previous studies assessing the relationship between diabetes and MDR TB 
primarily were among patients with prior history of TB treatment, while in our study we 
found that diabetes was associated with primary infection with MDR TB and reduced rate 
of sputum culture conversion during MDR TB treatment. Expanding our understanding 
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of the risk factors for primary infection of MDR TB, including the role of diabetes, is 
urgently needed in order to improve effective MDR TB prevention efforts.  
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TABLE – RESULT 
 
Table 3.1. Baseline characteristics and drug resistant profile among newly diagnosed adult TB patients in Tbilisi, Georgia, 
2011 – 2014 
 
Variable 
Type of Resistance 
Total 
N=268 P-Value 
Fully susceptibleA 
N % = 137 (51.12)  
< Fully Susceptible 
<MDRB 
N % = 79 (29.48) 
MDR and XDR TBC 
N % = 52 (19.40) 
N % N % N % N % 
Age  
   Median (IQR) 
 
   35 – 54 
   ≥ 55 
 
50 (41 – 58) 
 
89 (64.96) 
48 (35.05) 
 
48( 42 – 54) 
 
60 (75.95) 
19 (24.05) 
 
47 (42.5 – 58) 
 
35 (67.31) 
17 (32.69) 
 
49 (42 – 58) 
 
184 (68.66) 
84 (31.34) 
 
0.82 
 
0.24 
Sex 
   Female 
   Male 
 
37 (27.01) 
100 (72.99) 
 
14 (17.72) 
65 (82.28) 
 
15 (28.85) 
37 (71.15) 
 
66 (24.63) 
202 (75.37) 
 
0.24 
Education (formal years) 
   Median (IQR) 
 
   < High School completed (≤9) 
   High school (10 – 11) 
   > High School (≥12) 
 
11 (10 – 14) 
 
16 (11.76) 
68 (50.00) 
52 (38.24) 
 
11 (10 -14) 
 
10 (12.66) 
42 (53.16) 
27 (34.18) 
 
10 (10 – 11) 
 
4 (7.69) 
42 (80.77) 
6 (11.54) 
 
11 (10 – 14) 
 
30 (11.24) 
152 (56.93) 
85 (31.84) 
 
0.07 
 
<0.01 
 
 
Household Income (USD/Month) 
   Median (IQR) 
 
   ≤ $59 
   $60 - $176 
   ≥ $177 
 
176.47 (58.82 – 529.41) 
 
36 (26.28) 
42 (30.66) 
59 (43.07) 
 
117.65 (5.88– 411.76) 
 
27 (34.18) 
22 (27.85) 
30 (37.97) 
 
62.94 (0 – 205.88) 
 
25 (48.08) 
14 (26.92) 
13 (25.00) 
 
117.65 (41.18 – 411.77) 
 
88 (32.84) 
78 (29.10) 
102 (38.06) 
 
<0.01 
 
0.07 
 
Internally Displaced 
   No 
   Yes 
 
124 (90.51) 
13 (9.49) 
 
76 (96.20) 
3 (3.80) 
 
46 (88.46) 
6 (11.54) 
 
246 (91.79) 
22 (8.21) 
 
0.24 
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Variable 
Type of Resistance 
Total 
N=268 P-Value 
Fully susceptibleA 
N % = 137 (51.12)  
< Fully Susceptible 
<MDRB 
N % = 79 (29.48) 
MDR and XDR TBC 
N % = 52 (19.40) 
N % N % N % N % 
Imprisonment 
   No 
   Yes 
 
118 (86.13) 
19 (13.87) 
 
66 (83.54) 
13 (16.46) 
 
45 (86.54) 
7 (13.46) 
 
229 (85.45) 
39 (14.55) 
 
0.85 
Smoking Status 
   Never smoker 
   Past smoker 
   Current smoker 
 
39 (28.68) 
36 (26.47) 
61 (44.85) 
 
8 (10.13) 
24 (30.38) 
47 (59.49) 
 
14 (26.92) 
15 (28.85) 
23 (44.23) 
 
61 (22.85) 
75 (28.09) 
131 (49.06) 
 
0.04 
 
 
Alcohol Use 
   Never 
   Intermediate 
   Heavy 
 
45 (33.09) 
35 (25.74) 
56 (41.18) 
 
16 (20.25) 
20 (25.32) 
43 (54.43) 
 
19 (36.54) 
10 (19.23) 
23 (44.23) 
 
80 (29.96) 
65 (24.34) 
122 (45.69) 
 
0.18 
Contact with MDR-TB Patient 
   No 
   Yes 
 
126 (92.65) 
10 (7.35) 
 
68 (90.67) 
7 (9.33) 
 
47 (92.16) 
4 (7.84) 
 
241 (91.98) 
21 (8.02) 
 
0.88 
BMI  
   Median (IQR) 
 
   <18.5 
   18.5 – 24.9 
   ≥ 25 
 
21.19 (19.23 – 22.89) 
 
28 (21.05) 
91 (68.42) 
14 (10.53) 
 
21.55 (20.15 – 23.38) 
 
14 (18.42) 
51 (67.11) 
11 (14.47) 
 
21.48 (19.59 – 24.61) 
 
8 (15.38) 
33 (63.46) 
11 (21.15) 
 
21.30 (19.71 – 23.56) 
 
50 (19.16) 
175 (67.05) 
36 (13.79) 
 
0.34 
 
0.44 
Diabetes 
   Median Hba1c (IQR) 
 
   No Diabetes 
   Diabetes 
 
5.4 (5.1 – 5.7) 
 
120 (87.59) 
17 (12.41) 
 
5.5 (5.2 – 5.7) 
 
71 (89.87) 
8 (10.13) 
 
5.3 (5.2 – 5.85) 
 
41 (78.85) 
11 (21.15) 
 
5.4 (5.1 – 5.7) 
 
232 (86.57) 
36 (13.43) 
 
0.61 
 
0.18 
HIV Status 
   Negative 
   Positive 
 
128 (97.71) 
3 (2.29) 
 
75 (94.94) 
4 (5.06) 
 
49 (94.23) 
3 (5.77) 
 
252 (96.18) 
10 (3.83) 
 
0.45 
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Variable 
Type of Resistance 
Total 
N=268 P-Value 
Fully susceptibleA 
N % = 137 (51.12)  
< Fully Susceptible 
<MDRB 
N % = 79 (29.48) 
MDR and XDR TBC 
N % = 52 (19.40) 
N % N % N % N % 
Hypertension 
   No 
   Yes 
 
113 (82.48) 
24 (17.52) 
 
68 (86.08) 
11 (13.92) 
 
41 (78.85) 
11 (21.15) 
 
222 (82.84) 
46 (17.16) 
 
0.56 
Liver Disease 
   No 
   Yes 
 
118 (86.76) 
18 (13.24) 
 
70 (88.61) 
9 (11.39)  
 
39 (75.00) 
13 (25.00) 
 
227 (85.02) 
40 (14.98) 
 
0.08 
Kidney Disease 
   No 
   Yes 
 
126 (91.97) 
11 (8.03) 
 
69 (90.79) 
7 (9.21) 
 
44 (84.62) 
8 (15.38) 
 
239 (90.19) 
26 (9.81) 
 
0.32 
Cavitary disease 
   None 
   Any Cavity 
 
105 (81.40) 
24 (18.60) 
 
57 (73.08) 
21 (26.92) 
 
31 (59.62) 
21 (40.38) 
 
193 (74.52) 
66 (25.48) 
 
0.01 
Abbreviations: MDR – multi drug resistant; XDR – extensively drug resistant; IQR – interquartile range; HbA1c – hemoglobin A1c;  
A. Patients known to have all susceptible results for the TB first line drugs used in Georgia (Isoniazid, Rifampicin, Ethambutol, 
Streptomycin)  
B. Patients known to have at least one resistance to any TB first line drug (including patients with one or more missing susceptibility 
results for the TB first line drugs, but not MDR case) 
C. Patients known to have resistance for isoniazid and rifampicin, there were 49 patients of MDR TB and 3 patients of XDR TB 
Bold indicates that the finding is statistically significant at level of confidence of 5% (P value <0.05 
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Table 3.2 Polytomous regression for type of resistance among newly diagnosed adult TB patients in Tbilisi, Georgia, 2011 – 
2014 
 
 
 Variable 
Type of Resistance 
< Fully Susceptible (Not MDR)B vs 
Fully SusceptibleA 
M/XDRC vs Fully Susceptible 
COR (95%CI) AOR (95%CI)D COR (95%CI) AOR (95%CI)D 
Age  
   35 – 54 
   ≥ 55 
 
1 
0.59 (0.32 – 1.10) 
 
1 
0.72 (0.36 – 1.42) 
 
1 
0.90 (0.46 – 1.77) 
 
1 
0.94 (0.44 – 2.00) 
Sex 
   Female 
   Male 
 
1 
1.72 (0.86 – 3.42) 
 
1 
0.71 (0.25 – 2.04) 
 
1 
0.91 ( 0.45 – 1.85) 
 
1 
0.84 (0.27 – 2.61) 
Education (formal years) 
   < High School completed (≤9) 
   High school (10 – 11) 
   > High School (≥12) 
 
1.20 (0.48 – 3.01) 
1.19 (0.65 – 2.18) 
1 
  
2.17 (0.54 – 8.64) 
5.35 (2.12 – 13.55) 
1 
 
Household Income  
   ≤ $59 
   $60 - $176 
   ≥ $177 
 
1.48 (0.76 – 2.87) 
1.03 (0.52 – 2.03) 
1 
 
1.65 (0.81 – 3.36) 
1.14 (0.54 – 2.43) 
1 
 
3.15 (1.43 – 6.93) 
1.51 (0.65 – 3.55) 
1 
 
3.51 (1.56 – 8.20) 
1.78 (0.72 – 4.41) 
1 
Internally Displaced 
   No 
   Yes 
 
1 
0.38 (0.10 – 1.36) 
  
1 
1.24 (0.45 – 3.47) 
 
Imprisonment 
   No 
   Yes 
 
1 
1.22 (0.57 – 2.63) 
 
 
 
1 
0.97 (0.38 – 2.45) 
 
 
Smoking Status 
   Never smoker 
   Past smoker 
   Current smoker 
 
1 
3.25 (1.30 – 8.15) 
3.76 (1.60 – 8.79) 
 
1 
3.94 (1.25 – 12.47) 
4.56 (1.49 – 14.02) 
 
1 
1.16 (0.49 – 2.73) 
1.05 (0.48 – 2.28) 
 
1 
1.52 (0.48 – 4.76) 
1.52 (0.50 – 4.59) 
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 Variable 
Type of Resistance 
< Fully Susceptible (Not MDR)B vs 
Fully SusceptibleA 
M/XDRC vs Fully Susceptible 
COR (95%CI) AOR (95%CI)D COR (95%CI) AOR (95%CI)D 
Alcohol Use 
   Never 
   Intermediate 
   Heavy 
 
1 
1.61 (0.73 – 3.55) 
2.16 (1.08 – 4.33) 
 
1 
1.14 (0.42 – 3.07) 
1.28 (0.48 – 3.44) 
 
1 
0.68 (0.28 – 1.64) 
0.97 (0.47 – 2.01) 
 
1 
0.82 (0.27 – 2.47) 
0.93 (0.32 – 2.72) 
Contact with MDR-TB Patient 
   No 
   Yes 
 
1 
1.30 (0.47 – 3.56) 
  
1 
1.07 (0.32 – 3.59) 
 
 
BMI 
   <18.5 
   18.5 – 24.9 
   ≥ 25 
 
0.89 (0.43 – 1.85) 
1 
1.40 (0.59 – 3.31) 
  
0.79 (0.33 – 1.90) 
1 
2.17 (0.90 – 5.25) 
 
Diabetes 
   No Diabetes 
   Diabetes 
 
1 
0.80 (0.33 – 1.94) 
 
1 
1.20 (0.46 – 3.14) 
 
1 
1.89 (0.82 – 4.38) 
 
1 
2.51 (1.00  – 6.31) 
HIV Status 
   Negative 
   Positive 
 
1 
2.28 (0.50 – 10.45) 
 
1 
1.86 (0.39 – 8.89) 
 
1 
2.61 (0.51 – 13.38) 
 
1 
2.57 (0.47 – 14.05) 
Hypertension 
   No 
   Yes 
 
1 
0.76 (0.35 – 1.65) 
  
1 
1.26 (0.57 – 2.81) 
 
Liver Disease 
   No 
   Yes 
 
1 
0.84 (0.36 – 1.98) 
 
 
 
1 
2.19 (0.98 – 4.86) 
 
 
Kidney Disease 
   No 
   Yes 
 
1 
1.16 (0.43 – 3.13) 
 
1 
1.01 (0.35 – 2.91) 
 
1 
2.08 (0.79 – 5.51) 
 
1 
1.65 (0.59 – 4.63) 
Cavitary Disease 
   No  
   Yes 
 
1 
1.61 (0.83 – 3.15) 
 
 
 
1 
2.96 (1.48 – 6.03) 
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Abbreviations: MDR – multi drug resistant; XDR – extensively drug resistant; COR – Crude odds ratio; AOR – Adjusted 
odds ratio; CI – Confidence Interval 
A. Patients known to have all susceptible results for the TB first line drugs used in Georgia (Isoniazid, Rifampicin, 
Ethambutol, Streptomycin)  
B. Patients known to have at least one resistance to any TB first line drug (including patients with one or more missing 
susceptibility results for the TB first line drugs, but not MDR case) 
C. Patients known to have resistance among isoniazid and rifampicin 
D. Adjusted odds ratio after controlling for age, sex, socioeconomic status, smoking status, alcohol use, HIV status, 
diabetes status, and kidney disease. Empty cells mean that the variables were not included in the multivariate model. 
Bold indicates that the finding is statistically significant at level of confidence of 5% (P value <0.05)  
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Table 3.3 Univariate and multivariate hazard rate ratio analysis of patients’ characteristics and sputum culture conversion time 
among adult newly diagnosed MDR-TB patients in Tbilisi, Georgia, 2011 – 2014 
 
 
 
Characteristic 
Converted 
44/52 
(84.62%) 
Median 
(IQR)A 
cHR (95% CI) aHRB (95% CI) 
N % 
Age  
   35 – 54 
   ≥ 55 
 
30/35 (85.71) 
14/17 (82.35) 
 
60 (31 – 91) 
63 (32 – 94) 
 
1 
0.90 (0.47 – 1.72) 
 
1 
0.45 (0.19 – 1.06) 
Sex 
   Female 
   Male 
 
12/15 (80.00) 
32/37 (86.49) 
 
60 (29 – 63) 
62 (32 – 94) 
 
1 
0.50 (0.24 – 1.02) 
 
1 
1.45 (0.49 – 4.28) 
Household Income 
   ≤ $59 
   $60 - $176 
   ≥ $177 
 
22/25 (88.00) 
12/14 (85.71) 
10/13 (76.92) 
 
63 (32 – 92) 
47.5 (29 – 63) 
61 (31 – 94) 
 
0.97 (0.45 – 2.09) 
1.66 (0.71 – 3.87) 
1 
 
0.66 (0.25 – 1.72) 
0.93 (0.32 – 2.69) 
1 
Smoking Status 
   Never smoker 
   Past smoker 
   Current smoker 
 
12/14 (85.71) 
15/15 (100.00) 
17/23 (73.91) 
 
61.5 (29 – 87) 
60 (29 – 92) 
61 (32 – 99) 
 
1 
0.97 (0.45 – 2.10) 
0.44 (0.19 – 0.98) 
 
1 
0.60 (0.20 – 1.79) 
0.16 (0.04 – 0.61) 
Alcohol Use   
   Never 
   Intermediate 
   Heavy 
 
17/19 (89.47) 
9/10 (90.00) 
18/23 (78.26) 
 
62 (31 – 87) 
31.5 (27 – 99) 
60 (32 – 94) 
 
1 
1.06 (0.46 – 2.41) 
0.58 (0.29 – 1.15) 
 
Imprisonment 
   No 
   Yes 
 
38/45 (84.44) 
6/7 (85.71) 
 
61 (32 – 92) 
31 (29 – 84) 
 
1 
1.89 (0.78 – 4.57) 
 
Contact with MDR-TB Patient 
   No 
   Yes 
 
41/47 (87.23) 
2/4 (50.00) 
 
61 (32 – 92) 
14.5 (0 – 31.5) 
 
1 
3.54 (0.80  – 15.62) 
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Characteristic 
Converted 
44/52 
(84.62%) 
Median 
(IQR)A 
cHR (95% CI) aHRB (95% CI) 
N % 
Diabetes 
   No 
   Yes 
 
34/41 (82.93) 
10/11 (90.91) 
 
38 (31 – 84) 
87 (35 – 99) 
 
1 
0.75 (0.36 – 1.53) 
 
1 
0.34 (0.13 – 0.87) 
HIV Status 
   Negative 
   Positive 
 
42/49 (85.71) 
2/3 (66.67) 
 
61 (31 – 91) 
35 (29 – 126) 
 
1 
0.65 (0.15 – 2.73) 
 
1 
0.51 (0.09 – 3.06) 
BMI 
   <18.5 
   18.5 – 24.9 
   ≥25 
 
7/8 (87.50) 
29/33 (87.88) 
8/11 (72.73) 
 
30.5 (13.5 – 57) 
60 (32 – 94) 
63 (34 – 87) 
 
2.82 (1.18 – 6.75) 
1 
1.19 (0.53 – 2.68) 
 
Cavitary Disease 
   None 
   Any cavity 
 
25/31 (80.65) 
19/21 (90.48) 
 
61 (31 – 94) 
60 (31 – 91) 
 
1 
1.31 (0.71 – 2.40) 
 
1 
2.48 (1.04 – 5.90) 
AFB Smear (among Culture 
Positive) 
   Negative 
   Positive 
 
5/8 (62.50) 
35/39 (89.74) 
 
30.5 (24 – 57.5) 
61 (32 – 94) 
 
1 
0.66 (0.25 – 1.73) 
 
1 
0.56 (0.17 – 1.88) 
 
Abbreviations: MDR – multi drug resistant; IQR – interquartile range; cHR – crude hazard rate ratio; aHR – adjusted hazard rate 
ratio; BMI – body mass index; HbA1c – hemoglobin A1c;  
A. Among patients who converted, median time (measured in days) from the initial MDR-Treatment until the first two 
consecutive negative culture results (≥30 days apart) 
B. Hazard rate ratio after controlling for age, sex, socioeconomic, smoking status, diabetes status, HIV status, cavitary disease, 
and AFB smear. Empty cells mean that the variables were not included in the multivariate model 
Bold indicates that the finding is statistically significant at level of confidence of 5% (P value <0.05)  
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Figure 3.1. Time to sputum culture conversion among 52 primary MDR TB patients with and without diabetes in Tbilisi, 
Georgia, 2011 – 2014 
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Table a. Distribution of multidrug resistant tuberculosis and baseline characteristic among adult TB patients in Tbilisi, 
Georgia, 2011 – 2014 
Characteristic 
Non MDR-TB 
N = 266 
MDR-TBA 
N = 52 
Total 
OR  
(95% CI) 
P valueB 
N % N % N = 318 
Demographic Characteristic 
Age  
   Median, IQR 
 
   35 – 44 
   45 – 54 
   55 – 64  
   ≥ 65 
 
   35 – 44 
   45 – 54 
   ≥ 55 
 
   35 – 54 
   ≥ 55 
 
50.0 (42 – 58) 
 
86 (32.3) 
85 (32.0) 
58 (21.8) 
37 (13.9) 
 
86 (32.3) 
85 (32.0) 
95 (35.7) 
 
171 (64.3) 
95 (35.7) 
 
47.0 (42.5 – 58) 
 
20 (38.5) 
15 (28.8) 
13 (25) 
4 (7.7) 
 
20 (38.5) 
15 (28.9) 
17 (32.6) 
 
35 (67.3) 
17 (32.7) 
 
49.0 (42 – 58) 
 
106 (33.3) 
100 (31.5) 
71 (22.3) 
41 (12.9) 
 
106 (33.3) 
100 (31.5) 
112 (35.2) 
 
206 (64.8) 
112 (35.2)  
 
 
 
1 
0.76 (0.36 – 1.57) 
0.96 (0.44 – 2.07) 
0.47 (0.13 – 1.33) 
 
1 
0.76 (0.34 – 1.57) 
0.77 (0.38 – 1.56) 
 
1 
0.87 (0.47 – 1.64) 
 
0.41 
 
0.54 
 
 
 
 
0.69 
 
 
 
0.68 
 
Sex 
   Female 
   Male 
 
64 (24.1) 
202 (75.9) 
 
15 (28.8) 
37 (71.2) 
 
79 (24.8) 
239 (75.2) 
 
1 
0.78 (0.40 – 1.52) 
 
0.47 
Education (formal years) 
  Median (IQR) 
    
< High School completed (≤9) 
   High school (10 – 11) 
   > High School (≥12) 
 
11.0 (10 – 15) 
 
33 (12.4) 
133 (50.2) 
99 (37.4) 
 
10.0 (10 – 11) 
 
4 (7.7) 
42 (80.8) 
6 (11.5) 
 
11.0 (10 – 14) 
 
37 (11.7) 
175 (55.2) 
105 (33.1) 
 
 
 
2.00 (0.49 – 7.44) 
5.21 (2.29 – 14.09) 
1 
 
0.02 
 
<0.01 
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Characteristic 
Non MDR-TB 
N = 266 
MDR-TBA 
N = 52 
Total 
OR  
(95% CI) 
P valueB 
N % N % N = 318 
   ≤ High School (≤11) 
   > High School (≥12) 
166 (62.6) 
99 (37.4) 
46 (88.5) 
6 (11.5) 
212 (66.9) 
105 (33.1) 
4.57 (2.03 – 12.29) 
1 
<0.01 
Household Income (USD/Month) 
   Median (IQR) 
 
   ≤ $59 
   $60 - $176 
   ≥ $177 
 
Low SES (< $177) 
High SES (≥ $177) 
 
176.5 (58.5 – 470.6) 
 
77 (28.9) 
79 (29.7) 
110 (41.4) 
 
156 (58.7) 
110 (41.3) 
 
62.9 (0 – 205.9) 
 
25 (48.1) 
14 (26.9) 
13 ( 25.0) 
 
39 (75.0) 
13 (25.9) 
 
117.7 (41.2 – 411.8) 
 
102 (32.1) 
93 (29.25) 
123 (38.68) 
 
195 (61.3) 
123 (38.7) 
 
 
 
2.75 (1.34 – 5.85) 
2.28 (0.79 – 6.16) 
1 
 
2.12 (1.11 – 4.29) 
1 
 
<0.01 
 
0.02 
 
 
 
0.03 
 
Internally Displaced 
   No 
   Yes 
 
245 (92.1) 
21 (7.9) 
 
46 (88.5) 
6 (11.5) 
 
291 (91.5) 
27 (8.5) 
 
1 
1.5 (0.58 – 3.98) 
 
0.39 
Imprisonment 
   No 
   Yes 
 
231 (86.8) 
35 (13.2) 
 
45 (86.5) 
7 (13.5) 
 
276 (86.8) 
42 (13.2) 
 
1 
1.03 (0.43 – 2.46) 
 
0.95 
Smoking Status 
   Never smoker 
   Past smoker 
   Current smoker 
 
   Never/Past smoker 
   Current smoker 
 
61 (23.0) 
65 (24.5) 
139 (52.5) 
 
126 (47.5) 
139 (52.5) 
 
14 (26.9) 
15 (28.9) 
23 (44.2) 
 
29 (55.8) 
23 (44.2) 
 
76 (23.9) 
80 (25.2) 
162 (50.9) 
 
155 (48.9) 
162 (51.1) 
 
1 
1.02 (0.45 – 2.31) 
0.73 (0.36 – 1.55) 
 
1 
0.72 (0.40 – 1.31) 
 
0.57 
 
 
 
0.28 
Alcohol UseC 
   Never  
   Frequent/infrequent intermediate 
   Infrequent heavy 
   Frequent heavy 
 
75 (28.4) 
68 (25.8) 
77 (29.2) 
44 (16.6) 
 
19 (36.5) 
10 (19.2) 
16 (30.8) 
7 (13.5) 
 
94 (29.8) 
78 (24.7) 
93 (29.4) 
51 (16.1) 
 
1 
0.58 (0.24 – 1.31) 
0.82 (0.39 – 1.71) 
0.63 (0.23 – 1.56) 
 
0.56 
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Characteristic 
Non MDR-TB 
N = 266 
MDR-TBA 
N = 52 
Total 
OR  
(95% CI) 
P valueB 
N % N % N = 318 
   Never 
   Frequent/Infrequent intermediate 
   Frequent/Infrequent Heavy 
  
   Never 
   Frequent/Infrequent 
75 (28.4) 
68 (25.8) 
121 (45.8) 
 
75 (28.4) 
189 (71.6) 
19 (36.5) 
10 (19.2) 
23 (44.2) 
 
19 (36.5) 
33 (63.5) 
94 (29.8) 
78 (24.7) 
144 (45.5) 
 
94 (29.8) 
222 (70.2) 
1 
0.58 (0.24 – 1.31) 
0.75 (038 – 1.48) 
 
1 
0.69 (0.37 – 1.31) 
0.42 
 
 
 
0.24 
Contact with MDR-TB Patient 
   No 
   Yes 
 
243(93.1) 
18 (6.9) 
 
47 (92.2) 
4 (7.8) 
 
290 (92.9) 
22 (7.1) 
 
1 
1.15 (0.37 – 3.55) 
 
0.77 
Symptoms 
Cough 
   No 
   Yes 
 
58 (23.2) 
192 (76.8) 
 
10 (19.2) 
42 (80.8) 
 
68 (22.5) 
234 (77.5) 
 
1 
1.27 (0.60 – 2.69) 
 
0.53 
Hemoptysis 
   No 
   Yes 
 
191 (76.7) 
58 (23.3) 
 
42 (80.8) 
10 (19.2) 
 
233 (77.4) 
68 (22.6) 
 
1 
0.78 (0.37 – 1.66) 
 
0.52 
Chest Pain 
   No 
   Yes 
 
159 (64.1) 
89 (35.9) 
 
34 (65.4) 
18 (34.6) 
 
193 (64.3) 
107 (35.7) 
 
1 
0.95 (0.50 – 1.77) 
 
0.86 
Fever 
   No 
   Yes 
   Missing 
 
69 (39.9) 
104 (60.1) 
93 
 
3 (13.0) 
20 (87.0) 
29 
 
72 (36.7) 
124 (63.3) 
122 
 
1 
4.42 (1.27 – 15.46) 
 
0.01 
Weight loss 
   No 
   Yes 
   Missing 
 
62 (36.5) 
108 (63.5) 
96 
 
4 (17.4) 
19 (82.6) 
29 
 
66 (34.2) 
127 (65.8) 
125 
 
1 
2.73 (0.89 – 8.38) 
 
0.07 
Night sweats  
   No 
 
57 (33.7) 
 
10 (45.5) 
 
67 (35.1) 
 
1 
 
0.28 
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Characteristic 
Non MDR-TB 
N = 266 
MDR-TBA 
N = 52 
Total 
OR  
(95% CI) 
P valueB 
N % N % N = 318 
   Yes 
   Missing 
112 (66.3) 
97 
12 (54.5) 
30 
124 (64.9) 
127 
0.61 (0.25 – 1.50) 
 
Weakness 
   No 
   Yes 
   Missing 
 
38 (22.2) 
133 (77.8) 
95 
 
6 (27.3) 
16 (73.7) 
30 
 
44 (22.8) 
149 (77.20) 
125 
 
1 
0.76 (0.28 – 2.08) 
 
0.59 
Clinical Information 
Symptom to TB treatment time (days)  
   Median (IQR) 
 
   0 – 21 
   22-70 
   ≥71 
   Missing 
 
33 (18.5 – 105) 
 
63 (33.9) 
65 (35.0) 
58 (31.1) 
80 
 
44 (22 – 136) 
 
7 (19.4) 
15 (41. 7) 
14 (38.9) 
16 
 
35 (19 – 108) 
 
70 (31.5) 
80 (36.0) 
72 (32.5) 
96 
 
 
 
1 
2.08 (0.82 – 5.75) 
2.17 (0.84 – 6.08) 
 
 
0.37 
 
0.23 
 
Seek care to TB treatment time (days) 
   Median (IQR) 
 
   0 – 14 
   15 – 35 
   ≥36 
   Missing 
 
14 (1 – 37) 
 
114 (49.1) 
58 (25.0) 
60 (25.9) 
34 
 
14.5 (0.5 – 28.5) 
 
19 (46.4) 
14 (34.1) 
8 (19.5) 
11 
 
14 (1 – 14) 
 
133 (48.7) 
72 (26.4) 
68(24.9) 
45 
 
 
 
1 
1.45 (0.67 – 3.08) 
0.80 (0.31 – 1.88) 
 
0.51 
 
0.42 
BMI 
   Median (IQR) 
    
   <18.5 
   18.5 – 24.9 
   ≥25 
 
21.3 (19.7 – 23.4) 
 
46 (17.9) 
174 (67.7) 
37 (14.4) 
 
21.5 (19.6 – 24.6) 
 
8 (15.4) 
33 (63.5) 
11 (21.1) 
 
21.3 (19.7 – 23.6) 
 
54 (17.5) 
207 (70.0) 
48 (15.5) 
 
 
 
0.92 (0.37 – 2.04) 
1 
1.57 (0.70 – 3.31) 
 
0.47 
 
0.47 
Diabetes 
   Median HbA1c 
 
5.4 (5.1 – 5.7) 
 
5.3 (5.2 – 5.85) 
 
5.4 (5.1 – 5.7) 
 
 
 
0.87 
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Characteristic 
Non MDR-TB 
N = 266 
MDR-TBA 
N = 52 
Total 
OR  
(95% CI) 
P valueB 
N % N % N = 318 
   No Diabetes 
   Diabetes 
 
   No Diabetes 
   Pre Diabetes 
   Diabetes 
240 (90.2) 
26 (9.8) 
 
194 (72.9) 
46 (17.3) 
26 (9.8) 
41 (78.9) 
11 (21.1) 
 
35 (67.3) 
6 (11.5) 
11 (21.2) 
281 (88.4) 
37 (11.6) 
 
229 (72.0) 
52 (16.4) 
37 (11.6) 
1 
2.48 (1.14 – 5.40) 
 
1 
0.72 (0.26 – 1.71) 
2.35 (1.03 – 5.08) 
0.02 
 
 
0.05 
HIV Status 
   Negative 
   Positive 
   Unknown 
 
249 (93.6) 
9 (3.4) 
8 (3) 
 
49 (94.2) 
3 (5.8) 
0 (0.0) 
 
298 (93.7) 
12 (3.8) 
8 (2.5) 
 
1 
1.69 (0.37 – 5.91) 
<0.001 (. – 1.40) 
 
0.37 
Hypertension 
   No 
   Yes 
 
213 (81.0) 
50 (19.0) 
 
41 (78.9) 
11 (21.1) 
 
254 (80.6) 
61 (19.4) 
 
1 
1.14 (0.55 – 2.38) 
 
0.72 
Liver Disease 
   No 
   Yes 
 
226 (85.9) 
37 (14.1) 
 
39 (75.0) 
13 (25.0) 
 
265 (84.1) 
50 (15.9) 
 
1 
2.04 (0.99 – 4.17) 
 
0.05 
Kidney Disease 
   No 
   Yes 
 
240 (92.3) 
20 (7.7) 
 
44 (84.6) 
8 (15.4) 
 
284 (91.0) 
28 (9.0) 
 
1 
2.18 (0.90 – 5.26) 
 
0.11 
AFB Smear 
   Negative 
   Positive 
   Missing 
 
AFB Smear (among Culture Positive) 
   Negative 
   Positive 
   Missing 
 
 
89 (33.6) 
176 (66.4) 
1 
 
 
44 (21.2) 
164 (78.8) 
58 
 
 
10 (19.2) 
42 (80.8) 
0 
 
 
8 (17.0) 
39 (83.0) 
5 
 
 
99 (31.2) 
218 (68.8) 
1 
 
 
52 (20.4) 
203 (79.6) 
63 
 
 
1 
2.12 (1.02 – 4.43) 
 
 
 
1 
1.31 (0.57 – 3.00) 
 
 
 
0.04 
 
 
 
 
 
0.53 
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Characteristic 
Non MDR-TB 
N = 266 
MDR-TBA 
N = 52 
Total 
OR  
(95% CI) 
P valueB 
N % N % N = 318 
Grade (Among AFB positive) 
   1+ 
   2+ 
   3+ 
   4+ 
 
48 (27.4) 
54 (30.9) 
39 (22.3) 
34 (19.4) 
 
8 (19.0) 
16 (38.1) 
13 (31.0) 
5 (11.9) 
 
56 (25.8) 
70 (32.3) 
53 (24.0) 
39 (17.9) 
 
1 
1.78 (0.72 – 4.73) 
2.0 (0.77 – 5.52) 
0.88 (0.25 – 2.88) 
 
0.31 
Cavitary disease 
   None 
   Any cavity 
 
   Any cavity, unilateral 
   Any cavity, bilateral 
 
   Unilateral, left cavity 
   Unilateral, right cavity    
 
206 (81.1) 
48 (18.9) 
 
33 (68.8) 
15 (31.2) 
 
14 (42.4) 
19 (57.6) 
 
31 (59.6) 
21 (40.4) 
 
19 (90.5) 
2 (9.5) 
 
10 (52.6) 
9 (47.4) 
 
237 (77.5) 
69 (22.5) 
 
52 (75.4) 
17 (24.6) 
 
24 (46.2) 
28 (53.8) 
 
1 
2.9 (1.53 – 5.50) 
 
1 
0.23 (0.05 – 1.12) 
 
1 
0.66 (0.21 – 2.06) 
 
<0.01 
 
 
0.05 
 
 
0.47 
Infiltrate, upper left side 
   No 
   Yes 
 
109 (42.6) 
147 (57.4) 
 
22 (42.3) 
30 (57.7) 
 
131 (42.5) 
177 (57.5) 
 
1 
1.01 (0.55 – 1.85) 
 
0.97 
Infiltrate, lower left side 
   No 
   Yes 
 
169 (66.3) 
86 (33.7) 
 
39 (75.0) 
13 (25.0) 
 
208 (67.8) 
99 (32.2) 
 
1 
0.66 (0.33 – 1.30) 
 
0.22 
Infiltrate, upper right side 
   No 
   Yes 
 
65 (25.2) 
193 (74.8) 
 
18 (34.6) 
34 (65.4) 
 
83 (26.8) 
227 (73.2) 
 
1 
0.64 (0.34 – 1.20) 
 
0.16 
Infiltrate, lower right side 
   No 
   Yes 
 
158 (62.0) 
97 (38.0) 
 
43 (82.7) 
9 (17.3) 
 
201 (65.5) 
106 (34.5) 
 
1 
0.34 (0.15 – 0.73) 
 
<0.01 
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Abbreviations: MDR-TB-Multidrug resistant tuberculosis; IQR-interquartile range; BMI-body mass index; AFB-
acid-fast bacilli 
A. MDR-TB is defined as TB disease where the bacilli is resistant to at least isoniazid and rifampicin 
B. Two sided p-value acquired from Chi square and Fisher’s Exact test (categorical data) and Kruskal-Wallis test 
(continuous data) 
C. Alcohol use: heavy ≥5 drinks/setting; intermediate ≤4 drinks/setting; frequent ≥3days/week; infrequent 
≤2days/week 
Statistical Tests: Categorical: Chi square test and Fisher’s exact test. Continuous: Kruskal-Wallis test 
Bold indicates that the finding is statistically significant at level of confidence of 5% (P value <0.05)  
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Table b. Distribution of low socioeconomic status and baseline characteristic among adult TB patients in Tbilisi, Georgia, 
2011 – 2014 
Characteristic 
Low SESA 
N = 195 
High SESB 
N = 123 
Total 
OR  
(95% CI) 
P 
valueC 
N % N % N = 318 
Demographic Characteristic 
Age  
   Median, IQR 
 
   35 – 44 
   45 – 54 
   55 – 64  
   ≥ 65 
 
   35 – 44 
   45 – 54 
   ≥ 55 
 
   35 – 54 
   ≥ 55 
 
51 (43 – 61) 
 
61 (31.3) 
59 (30.1) 
43 (22.1) 
32 (16.4) 
 
61 (31.3) 
59 (30.3) 
75 (38.5) 
 
120 (61.5) 
75 (38.5) 
 
47 (41 – 58) 
 
45 (36.6) 
41 (33.3) 
28 (22.8) 
9 (7.3) 
 
45 (36.6) 
41 (33.3) 
37 (30.1) 
 
86 (69.9) 
37 (30.1) 
 
49.0 (42 – 58) 
 
106 (33.3) 
100 (31.5) 
71 (22.3) 
41 (12.9) 
 
106 (33.3) 
100 (31.5) 
112 (35.2) 
 
206 (64.8) 
112 (35.2)  
 
 
 
1 
1.21 (0.73 – 2.03) 
1.09 (0.62 – 1.93) 
0.98 (0.52 – 1.83) 
 
1 
1.21 (0.73 – 2.03) 
1.04 (0.64 – 1.71) 
 
1 
0.94 (0.62 – 1.43) 
 
 
 
0.87 
 
 
 
 
0.73 
 
 
 
0.79 
 
Sex 
   Female 
   Male 
 
48 (24.6) 
147 (75.4) 
 
31 (25.2) 
92 (74.8) 
 
79 (24.8) 
239 (75.2) 
 
1 
0.97 (0.58 – 1.63) 
 
0.91 
Education (formal years) 
   Median (IQR) 
 
   < High School completed (≤9) 
   High school (10 – 11) 
   > High School (≥12) 
 
   ≤ High School (≤11) 
 
10.0 (10 – 11) 
 
30 (15.5) 
131 (67.5) 
33 (17.0) 
 
161 (83.0) 
 
13.0 (11 – 15) 
 
7 (5.7) 
44 (35.8) 
72 (58.5) 
 
51 (41.5) 
 
11.0 (10 – 14) 
 
37 (11.7) 
175 (55.2) 
105 (33.1) 
 
212 (66.9) 
 
 
 
9.35 (3.91 – 25.18) 
6.50 (3.84 – 11.22) 
1 
 
6.89 (4.14 – 11.69) 
 
 
 
<0.01 
 
 
 
<0.01 
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Characteristic 
Low SESA 
N = 195 
High SESB 
N = 123 
Total 
OR  
(95% CI) 
P 
valueC 
N % N % N = 318 
   > High School (≥12) 33 (17.0) 72 (58.5) 105 (33.1) 1 
Internally Displaced 
   No 
   Yes 
 
176 (90.3) 
19 (9.7) 
 
115 (93.5) 
8 (6.5) 
 
291 (91.5) 
27 (8.5) 
 
1 
1.6 (0.68 – 3.87) 
 
0.39 
Imprisonment 
   No 
   Yes 
 
167 (85.6) 
28 (14.4) 
 
109 (88.6) 
14 (11.4) 
 
276 (86.8) 
42 (13.2) 
 
1 
1.31 (0.67 – 2.66) 
 
0.45 
Smoking Status 
   Never smoker 
   Past smoker 
   Current smoker 
 
47 (24.1) 
53 (27.2) 
95 (48.7) 
 
29 (23.6) 
27 (21.9) 
67 (54.5) 
 
76 (23.9) 
80 (25.16) 
162 (50.94) 
 
1 
1.24 (0.64 – 2.39) 
0.89 (0.50 – 1.56) 
 
0.52 
Alcohol UseD 
   Never  
   Frequent/infrequent intermediate 
   Infrequent heavy 
   Frequent heavy 
 
   Never 
   Frequent/infrequent intermediate 
   Frequent/infrequent Heavy 
 
  Never 
   Frequent/infrequent 
 
64 (32.8) 
43 (22.1) 
51 (26.2) 
37 (18.9) 
 
64 (32.8) 
43 (22.1) 
88 (45.1) 
 
64 (32.8) 
131 (67.2) 
 
30 (24.8) 
78 (24.7) 
93 (28.4) 
51 (16.1) 
 
30 (24.8) 
35 (28.9) 
56 (46.3) 
 
30 (24.8) 
91 (75.2) 
 
94 (29.8) 
78 (24.7) 
93 (29.4) 
51 (16.1) 
 
94 (29.8) 
78 (24.7) 
144 (45.5) 
 
94 (29.8) 
222 (70.2) 
 
1 
0.58 (0.31 – 1.07) 
0.57 (0.31 – 1.03) 
1.24 (0.59 – 2.68) 
 
1 
0.58 (0.31 – 1.07) 
0.74 (0.43 – 1.27) 
 
1 
0.68 (0.40 – 1.12) 
 
0.06 
 
 
 
 
0.22 
 
 
 
0.13 
Contact with MDR-TB Patient 
   No 
   Yes 
 
170 (89.9) 
19 (10.1) 
 
120 (97.6) 
3 (2.4) 
 
290 (92.9) 
22 (7.1) 
 
1 
4.47 (1.48 – 19.32) 
 
0.02 
Clinical Information 
BMI 
   Median (IQR) 
 
20.9 (18.8 – 23.1) 
 
22.7 (20.4 – 24.7) 
 
21.3 (19.7 – 23.6) 
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Characteristic 
Low SESA 
N = 195 
High SESB 
N = 123 
Total 
OR  
(95% CI) 
P 
valueC 
N % N % N = 318 
    
   <18.5 
   18.5 – 24.9 
   ≥25 
 
44 (23.5) 
122 (65.9) 
21 (11.2) 
 
10 (8.2) 
85 (69.7) 
27 (22.1) 
 
54 (17.5) 
207 (70.0) 
48 (15.5) 
 
3.07 (1.52 – 6.76) 
1 
0.54 (0.29 – 1.02) 
 
<0.01 
Diabetes 
   Median Hba1c (IQR) 
 
   No Diabetes 
   Diabetes 
 
   No Diabetes 
   Pre Diabetes 
   Diabetes 
 
5.4 (5.1 – 5.7) 
 
176 (90.3) 
19 (9.7) 
 
138 (70.8) 
38 (19.5) 
19 (9.7) 
 
5.4 (5.2 – 5.6) 
 
105 (85.4) 
18 (14.6) 
 
91 (74.0) 
14 (11.4) 
18 (14.6) 
 
5.4 (5.1  - 5.7) 
 
281 (88.4) 
37 (11.6) 
 
229 (72.0) 
52 (16.4) 
37 (11.6) 
 
 
 
1 
0.97 (0.70 – 1.35) 
 
1 
1.79 (0.94 – 3.59) 
0.70 (0.35 – 1.41) 
 
 
 
0.18 
 
 
0.10 
HIV Status 
   Negative 
   Positive 
   Unknown 
 
182 (93.3) 
6 (3.1) 
7 (3.6) 
 
116 (94.3) 
6 (4.9) 
1 (0.8) 
 
298 (93.7) 
12 (3.8) 
8 (2.5) 
 
1 
0.64 (0.20 – 2.08) 
 
 
0.45 
Hypertension 
   No 
   Yes 
 
161 (83.9) 
31 (16.1) 
 
93 (75.6) 
30 (24.4) 
 
254 (80.6) 
61 (19.4) 
 
1 
0.59 (0.34 – 1.05) 
 
0.07 
Liver Disease 
   No 
   Yes 
 
160 (82.9) 
33 (17.1) 
 
105 (86.1) 
17 (13.9) 
 
265 (84.1) 
50 (15.9) 
 
1 
1.27 (0.68 – 2.45) 
 
0.45 
Kidney Disease 
   No 
   Yes 
 
167 (88.4) 
22 (11.6) 
 
117 (95.1) 
6 (4.9) 
 
284 (91.0) 
28 (9.0) 
 
1 
2.57 (1.07 – 7.15) 
 
0.05 
Cavitary Disease 
   No 
   Yes 
 
132 (71.0) 
54 (29.0) 
 
105 (87.5) 
15 (12.5) 
 
237 (77.5) 
69 (22.5) 
 
1 
2.86 (1.56 – 5.52) 
 
<0.01 
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Characteristic 
Low SESA 
N = 195 
High SESB 
N = 123 
Total 
OR  
(95% CI) 
P 
valueC 
N % N % N = 318 
Infiltrate, upper left side 
   No 
   Yes 
 
70 (37.2) 
118 (62.8) 
 
61 (50.8) 
59 (49.2) 
 
131 (42.5) 
177 (57.5) 
 
1 
1.74 (1.10 – 2.78) 
 
 
0.02 
Infiltrate, lower left side 
   No 
   Yes 
 
120 (63.8) 
68 (36.2) 
 
88 (73.9) 
31 (26.1) 
 
208 (67.8) 
99 (32.2) 
 
1 
1.61 (0.98 – 2.69) 
 
 
0.06 
Infiltrate, upper right side 
   No 
   Yes 
 
54 (28.6) 
135 (71.4) 
 
29 (24.0) 
92 (76.0) 
 
82 (26.8) 
227 (73.2) 
 
1 
0.79 (0.46 – 1.32) 
 
 
0.37 
Infiltrate, lower right side 
   No 
   Yes 
 
121 (64.7) 
66 (35.3) 
 
80 (66.7) 
40 (33.3) 
 
201 (65.5) 
106 (34.5) 
1 
1.09 (0.67 – 1.78) 
 
0.72 
 
Abbreviations: SES-socioeconomic status; IQR-interquartile range; BMI-body mass index;  
A. Low SES is defined as household income less than  US $177 per month 
B. High SES is defined as household income greater or equal to US $177 per month 
C. Two sided p-value acquired from Chi square and Fisher’s Exact test (categorical data) and Kruskal-Wallis test 
(continuous data) 
D. Alcohol use: heavy ≥5 drinks/setting; intermediate ≤4 drinks/setting; frequent ≥3days/week; infrequent 
≤2days/week 
Statistical Tests: Categorical: Chi square test and Fisher’s exact test. Continuous: Kruskal-Wallis test 
Bold indicates that the finding is statistically significant at level of confidence of 5% (P value <0.05)  
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Table c. Multivariate analysis for estimation of MDR-TB prevalence among new adult TB patients in Tbilisi, Georgia, 
2011 – 2014   
 
Variables 
N =318 
Prevalence of 
MDR TB (%) 
COR (95%CI) AOR (95%CI) P multivariate 
Age 
   35 – 54 
   ≥ 55 
 
16.99 
15.18 
 
1 
0.87 (0.47 – 1.64 
 
1 
0.79 (0.40 – 1.54) 
 
0.50 
Sex 
   Female 
   Male 
 
18.99 
15.48 
 
1 
0.78 (0.40 – 1.52) 
 
1 
0.91 (0.43 – 1.97) 
 
0.80 
SES 
   Low SES (<177) 
   High SES ≥ $177 
 
20.00 
10.57 
 
2.12 (1.11 – 4.29) 
1 
 
2.09 (1.03 – 4.44) 
1 
 
0.05 
Smoking Status 
   Never/past smoker 
   Current smoker 
 
18.71 
14.20 
 
1 
0.72 (0.40 – 1.31) 
 
1 
0.80 (0.40 – 1.60) 
 
0.53 
HIV Status 
   Negative 
   Positive 
 
16.96 
25.00 
 
1 
1.69 (0.44 – 6.48) 
 
1 
1.79 (0.37 – 6.77) 
 
0.42 
Diabetes 
   No Diabetes 
   Diabetes 
 
14.59 
29.73 
 
1 
2.48 (1.14 – 5.40) 
 
1 
2.24 (0.93 – 5.16) 
 
0.06 
Kidney  Disease 
   No 
   Yes 
 
15.49 
28.57 
 
1 
2.04 (0.99 – 4.17) 
 
1 
1.65 (0.62 – 4.07) 
 
0.29 
Cavitary Disease 
   No 
   Yes 
 
13.08 
30.44 
 
1 
2.9 (1.53 – 5.50) 
 
1 
2.24 (1.14 – 4.36) 
 
0.02 
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Abbreviations: COR - crude odds ratio; AOR – adjusted odds ratio; CI – confidence interval  
A. Adjusted model when variable age, smoking status, and household income were categorized as dichotomous 
(Age:  35 – 54/ ≥55; Smoking: never/past and current smoker; Household income: <$177/≥177) 
B. In addition to age and sex, adjusted model included household income as indicators for Socio-economy 
status 
Bold indicates that the finding is statistically significant at level of confidence of 5% (P value <0.05)  
 
